Search results for "Drug Combinations"

showing 10 items of 180 documents

Inhalation solutions — Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers — Update 2013

2014

AbstractMany patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in vitro studies and a thorough literature search.Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients contained in some of the tested drug products could be identified as a reason for i…

Lung DiseasesPulmonary and Respiratory MedicineDrugmedicine.medical_specialtymedia_common.quotation_subjectReviewCompatibilityAdministration InhalationmedicineMixtureHumansPediatrics Perinatology and Child HealthClinical efficacyIntensive care medicineAerosolmedia_commonInhalationbusiness.industryNebulizers and VaporizersDornase alfaAnti-Bacterial AgentsBronchodilator AgentsChemical compatibilityDrug CombinationsNebulizerNebulizer solution/suspensionAnesthesiaChronic DiseasePediatrics Perinatology and Child Healthbusinessmedicine.drugJournal of Cystic Fibrosis
researchProduct

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Dental stem cell signaling pathway activation in response to hydraulic calcium silicate-based endodontic cements: A systematic review of in vitro stu…

2020

Abstract Objective To present a qualitative synthesis of in vitro studies which analyzed human dental stem cell (DSC) molecular signaling pathway activation in response to hydraulic calcium silicate-based cements (HCSCs). Methods A systematic electronic search was performed in Medline, Scopus, Embase, Web of Science and SciELO databases on January 20 and last updated on March 20, 2020. In vitro studies assessing the implication of signaling pathways in activity related marker (gene/protein) expression and mineralization induced by HCSCs in contact with human DSCs were included. Results The search identified 277 preliminary results. After discarding duplicates, and screening of titles, abstr…

MAPK/ERK pathwayMaterials scienceCellDental CementsBiocompatible Materials02 engineering and technologySMADBiological FactorsDental Materials03 medical and health sciences0302 clinical medicineCa2+/calmodulin-dependent protein kinaseMedicine and Health SciencesmedicineHumansdental stem cellsGeneral Materials ScienceGeneral DentistryBiomedical and Dental MaterialsFOS: Clinical medicineSilicatesStem CellsIn vitro toxicologyWnt signaling pathwayEndodontics and Endodontologycalcium silicate-based cementsin vitroOxides030206 dentistryCalcium Compoundsbiomineralization021001 nanoscience & nanotechnologysignaling pathwaysChemicals and DrugsCell biologyDrug Combinationsmedicine.anatomical_structurebioactivityMechanics of MaterialsDentistryStem cellSignal transduction0210 nano-technologySignal TransductionDental Materials
researchProduct

Prognostic Factors after Endodontic Microsurgery: A Retrospective Study of 111 Cases with 5 to 9 Years of Follow-up

2021

A study was performed of the healing rate of teeth subjected to endodontic microsurgery after a minimum follow-up of 5 years with an analysis of the influence of different pre- and postoperative factors on the outcome.This was a retrospective study of patients subjected to endodontic microsurgery with the use of mineral trioxide aggregate (MTA) for retrograde filling between January 2011 and December 2015. In patients with multiple treated teeth, only 1 random tooth was selected for the statistical analysis. Clinical and radiographic parameters were used to assess healing. Simple binary logistic regression models were used to analyze the influence of patient age and sex, the type of tooth, …

Male0301 basic medicineMineral trioxide aggregateMolarMicrosurgeryRadiographyRoot canalDentistryEndodontic microsurgeryRoot Canal Filling MaterialsLesion03 medical and health sciences0302 clinical medicinestomatognathic systemHumansMedicineGeneral DentistryAnterior teethRetrospective Studiesbusiness.industryOxidesRetrospective cohort study030206 dentistryPrognosisRoot Canal TherapyDrug Combinationsstomatognathic diseasesTreatment Outcome030104 developmental biologymedicine.anatomical_structureFemalemedicine.symptombusinessFollow-Up StudiesJournal of Endodontics
researchProduct

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic …

2016

[Purpose] TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.

Male0301 basic medicineOncologyCancer ResearchPyrrolidinesColorectal cancerTrifluridineHelsinki declarationlaw.inventionTrifluridinechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicineAged 80 and overMetastatic colorectal cancerPalliative CareHazard ratioGeneral MedicineMiddle AgedPrognosisTAS-102Survival RateDrug CombinationsOncology030220 oncology & carcinogenesisDrug Therapy CombinationFemaleColorectal NeoplasmsFluoropyrimidineResearch Articlemedicine.drugAdultmedicine.medical_specialtyanimal structuresSubgroup analysisPlaceboAntiviral Agents03 medical and health sciencesDouble-Blind MethodInternal medicineHumansTipiracil hydrochlorideUracilAgedNeoplasm StagingTipiracilbusiness.industrymedicine.diseaseSurgery030104 developmental biologychemistrySpainbusinessThymineFollow-Up StudiesClinical and Translational Oncology
researchProduct

Methodological Approach to Use Fresh and Cryopreserved Vessels as Tools to Analyze Pharmacological Modulation of the Angiogenic Growth

2016

The sprouting of new vessels is greatly influenced by the procedure chosen. We sought to optimize the experimental conditions of the angiogenic growth of fresh and cryopreserved vessels cultured in Matrigel with the aim to use this system to analyze the pharmacological modulation of the process. Segments of second-order branches of rat mesenteric resistance arteries, thoracic aorta of rat or mouse, and cryopreserved rat aorta and human femoral arteries were cultured in Matrigel for 7-21 days in different mediums, as well as in the absence of endothelial or adventitia layer. Quantification of the angiogenic growth was performed by either direct measurement of the mean length of the neovessel…

Male0301 basic medicinemedicine.medical_treatmentNeovascularization PhysiologicAorta Thoracic030204 cardiovascular system & hematologycryopreservationFibroblast growth factorhuman vesselsNeovascularizationAndrologyangiogenesisMice03 medical and health scienceschemistry.chemical_compoundOrgan Culture Techniques0302 clinical medicinemedicine.arteryAdventitiamatrigelmedicineAnimalsHumansThoracic aortaRats WistarCryopreservationPharmacologyAortaMatrigelGrowth factorarterial ring assayRatsVascular endothelial growth factorDrug Combinations030104 developmental biologymedicine.anatomical_structurechemistryAdrenergic alpha-1 Receptor Antagonistscardiovascular systemProteoglycansAdrenergic alpha-1 Receptor AgonistsCollagenLamininmedicine.symptomCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology
researchProduct

Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort.

2021

Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co-medicated HCV patients was evaluated. Methods We prospectively evaluated consecutive patients from 15 clinical centres participating in PITER who were treated with ELB/GZR and had been followed for at least 12 weeks after treatment. Data were prospectively collected on the use of comedications (including discontinuation, dose modification and addition of drugs) and potential DDIs with DAAs. Results Of the 356 patients with at least 12-week post-t…

Male030312 virologycombination therapytreatment experienced patientsDrug Combinationchronic hepatitis C drug drug interactions virus genotype 1 treatment experienced patients pump inhibitor use combination therapy treatment naive liver fibrosisgrazoprevir elbasvir80 and overAge FactorPharmacology (medical)Drug InteractionsProspective StudiesChronicProspective cohort studyliver fibrosisAged 80 and over0303 health sciencesAge FactorsImidazolesMiddle AgedHepatitis CDrug CombinationsInfectious DiseasesTreatment OutcomeDrug InteractionGrazoprevirCohortdrug drug interactionsFemalepump inhibitor useHumanmedicine.drugmedicine.medical_specialtyElbasvirQuinoxalinetreatment naiveelbasvirAntiviral AgentsNO03 medical and health sciencesInternal medicineQuinoxalinesmedicinechronic hepatitis CElbasvir GrazoprevirHumansImidazoleAgedBenzofuransAntiviral AgentPharmacology...business.industrygrazoprevirCarbamazepineHepatitis C Chronicmedicine.diseaseComorbidityDiscontinuationBenzofuranAge Factors; Aged; Aged 80 and over; Antiviral Agents; Benzofurans; Drug Combinations; Drug Interactions; Female; Hepatitis C Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Treatment Outcomebusinessvirus genotype 1Antiviral therapy
researchProduct

In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-ac…

2009

The effects of nitric oxide-active drugs on the anticonvulsant action of the antiepileptic drug levetiracetam in an experimental model of partial complex seizures named maximal dentate gyrus activation were studied in rats. Levetiracetam was given alone or in combination with 7-nitroindazole, a preferential inhibitor of neuronal nitric oxide synthase, or with L: -arginine, the precursor of nitric oxide synthesis. The maximal dentate activation parameters were the time of latency and the durations of maximal dentate activation and afterdischarge responses. The administration of levetiracetam showed an anticonvulsant effect that was increased when given in combination with 7-nitroindazole. Th…

Male7-NitroindazoleIndazolesLevetiracetamMaximal dentate activation - Nitric oxide - Levetiracetam - Modulation - 7-Nitroindazolemedicine.medical_treatmentNitric Oxide Synthase Type IPharmacologyArginineNitric OxideSettore BIO/09 - FisiologiaNitric oxideEpilepsychemistry.chemical_compoundEpilepsy Complex PartialmedicineAnimalsDrug InteractionsEnzyme InhibitorsRats WistarMaximal dentate activation Nitric oxide Levetiracetam Modulation 7-NitroindazoleBiological PsychiatryDose-Response Relationship DrugChemistryDentate gyrusPiracetammedicine.diseaseEffective dose (pharmacology)PiracetamRatsPsychiatry and Mental healthDisease Models AnimalDrug CombinationsAnticonvulsantNeurologyDentate GyrusAnticonvulsantsNeurology (clinical)Levetiracetammedicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational…

2021

Abstract Background and Aims The MARS post-marketing, observational study evaluates glecaprevir/pibrentasvir in a large population of Italian patients who are infected with HCV. Patients and Methods Achievement of SVR12 was the primary endpoint in the overall population and by subpopulations of interest (treatment-naive and treatment-experienced patients, subjects infected with different HCV genotype/sub-genotype, cirrhotic and non-cirrhotic patients, patients with different severity of fibrosis, patients with an APRI score ≥1, subjects with comorbidities, HIV-coinfected patients, elderly patients and people who use drugs). Safety and quality of life (assessed by SF-36 and Work Productivity…

MaleAdultmedicine.medical_specialtyPyrrolidinesQuinoxalineSustained Virologic ResponseSettore MED/12 - GASTROENTEROLOGIAPopulationAntiviral AgentselderlyBenzimidazoleGLE/PIBQuinoxalinesInternal medicineDrug CombinationClinical endpointmedicineProduct Surveillance PostmarketingHumansProspective StudieseducationAdverse effectAgedAntiviral AgentSulfonamideseducation.field_of_studyHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGastroenterologyPWUDGlecaprevirMiddle Agedelderly; GLE/PIB; HCV; PWUDHepatitis C ChronicPibrentasvirDiscontinuationDrug CombinationsGLE/PIB; HCV; PWUD; elderlyItalyCohortHCVQuality of LifeBenzimidazolesFemaleObservational studybusiness
researchProduct

Pregabalin as add-on treatment to botulinum toxin in idiopathic hemifacial spasm

2007

Botulinum toxin (BTX) is the medical therapy of choice in hemifacial spasm (HFS). However, in some patients, its therapeutic effect is insufficient. ### Patient 1. A 64-year-old man with a 10-year history of left-sided HFS was treated with BTX over a period of 6 years with good results. However, in the last 2 years the spasms were never sufficiently relieved by BTX. The patient felt significantly impaired, but declined to undergo neurosurgical intervention. The EDB test showed a decrease in the CMAP amplitude of 60%. Without changing the BTX regime, pregabalin (initially 75 mg/day increased every 5 days by 75 mg to 150 mg twice daily) was added for a 1-month trial period in the absence of a…

MaleBotulinum ToxinsPregabalinPregabalinPhysiology (medical)medicineHumansHemifacial SpasmAdverse effectgamma-Aminobutyric AcidAnti-Dyskinesia Agentsbusiness.industryTherapeutic effectMiddle Agedmedicine.diseaseBotulinum toxinSensory SystemsDiscontinuationDrug CombinationsTreatment OutcomeAdd on treatmentNeurologyAnesthesiaAnticonvulsantsFemaleNeurology (clinical)businessMedical therapymedicine.drugHemifacial spasmNeurology
researchProduct